{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:06:15Z","timestamp":1762067175337},"reference-count":37,"publisher":"BMJ","issue":"6333","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"published-print":{"date-parts":[[1982,6,26]]},"DOI":"10.1136\/bmj.284.6333.1908","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T15:00:59Z","timestamp":1238684459000},"page":"1908-1911","source":"Crossref","is-referenced-by-count":89,"title":["Bromocriptine in management of large pituitary tumours."],"prefix":"10.1136","volume":"284","author":[{"given":"J A","family":"Wass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Charlesworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D P","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Doniach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L H","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W I","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"Besser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/bmj.3.5828.669","article-title":"Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine","volume":"3","author":"Besser, G.M.; Parke, L.; Edwards, C.R.W.; Forsyth, I.A.; McNeilly, A.S.","year":"1972","unstructured":"Besser GM, Parke L, Edwards CRW, Forsyth IA, McNeilly AS. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med 3 1972;iii:669-72.","journal-title":"Br Med"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM197810192991602","article-title":"Prolactin secreting tumours and hypogonadism in 22 men","volume":"299","author":"Carter, J.N.; Tyson, J.E.; Tolis, G.; Van Vliet, S.; Faiman, C.; Friesen, H.G.","year":"1978","unstructured":"Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin secreting tumours and hypogonadism in 22 men. N Engl3' Med 1978;299:847-52.","journal-title":"N Engl3' Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2265.1978.tb02770.x","article-title":"Hyperprolactinaemia and impotence","volume":"8","author":"Franks, S.; Jacobs, H.S.; Martin, N.; Nabarro, J.D.N.","year":"1978","unstructured":"Franks S, Jacobs HS, Martin N, Nabarro JDN. Hyperprolactinaemia and impotence. Clin Endocrinol (Oxf) 1978;8:277-87.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref_4","first-page":"419","article-title":"Long term treatment of galactorrhoea and hypogonadism with bromocriptine","volume":"ii:","author":"Thorner, M.O.; McNeilly, A.S.; Hagan, C.; Besser, G.M.","year":"1974","unstructured":"Thorner MO, McNeilly AS, Hagan C, Besser GM. Long term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med3r 1974; ii:419-22."},{"key":"ref_5","first-page":"875","article-title":"Long-term treatment of acromegaly with bromocriptine","volume":"i:","author":"Wass, J.A.H.; Thorner, M.O.; Morris, D.V.; Rees, L.H.; Stuart Mason, A.; Jones, A.E.; Besser, G.M.","year":"1977","unstructured":"Wass JAH, Thorner MO, Morris DV, Rees LH, Stuart Mason A, Jones AE, Besser GM. Long-term treatment of acromegaly with bromocriptine. Br Med _] 1977;i:875-8.","journal-title":"Br Med _]"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/acta.0.0850235","article-title":"Long-term treatment with 2-Br-x-ergocryptine in acromegaly","volume":"85","author":"Belforte, L.; Cammani, F.; Chiodini, P.G.","year":"1977","unstructured":"Belforte L, Cammani F, Chiodini PG, et al. Long-term treatment with 2-Br-x-ergocryptine in acromegaly. Acta Endocrinol (Kbh) 1977;85: 235-48.","journal-title":"Acta Endocrinol (Kbh)"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(77)92959-2","article-title":"Prevalence and presentation of hyperprolactinaemia in patients with functionless pituitary tumours","volume":"i:","author":"Franks, S.; Nabarro, J.D.N.; Jacobs, H.S.","year":"1977","unstructured":"Franks S, Nabarro JDN, Jacobs HS. Prevalence and presentation of hyperprolactinaemia in patients with functionless pituitary tumours. Lancet 1977;i:778-80.","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ana.410020210","article-title":"Prolactin-secreting pituitary tumors","volume":"2","author":"Antunes, J.L.; Housepian, F.M.; Frantz, A.G.","year":"1977","unstructured":"Antunes JL, Housepian FM, Frantz AG, et al. Prolactin-secreting pituitary tumors. Ann Neurol 1977;2:148-53.","journal-title":"Ann Neurol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2265.1981.tb00618.x","article-title":"Pituitary function in prolactinoma. Effect of surgery and post operative bromocriptine therapy","volume":"14","author":"Pelkonen, R.; Grahne, B.; Hirvonen, E.","year":"1981","unstructured":"Pelkonen R, Grahne B, Hirvonen E, et al. Pituitary function in prolactinoma. Effect of surgery and post operative bromocriptine therapy. Clin Endocrinol (Oxf) 1981;14:335-48.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref_10","first-page":"614","article-title":"Possible anti-tumour effect of 2-bromo-ergocryptine (CB-154 Sandoz) in 2 patients with large prolactin-secreting pituitary adenomas","volume":"23","author":"Corenblum, B.; Webster, B.R.; Mortimer, C.B.; Ezrin, C.","year":"1975","unstructured":"Corenblum B, Webster BR, Mortimer CB, Ezrin C. Possible anti-tumour effect of 2-bromo-ergocryptine (CB-154 Sandoz) in 2 patients with large prolactin-secreting pituitary adenomas. Clinical Research 1975;23:614A.","journal-title":"Clinical Research"},{"key":"ref_11","first-page":"632","article-title":"Normalisation of visual fields following bromocriptine treatment in hyperprolactinaemic patients with visual field constriction","volume-title":"Fertil Steril","volume":"29","author":"Vaidya, R.A.; Aloorkar, S.D.; Rege, N.R.","year":"1978","unstructured":"Vaidya RA, Aloorkar SD, Rege NR, et al. Normalisation of visual fields following bromocriptine treatment in hyperprolactinaemic patients with visual field constriction. Fertil Steril 1978;29:632-6."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2265.1977.tb03343.x","article-title":"The use of bromocriptine in the galactorrhoeaamenorrhoea syndromes: the Canadian co-operative study","volume":"6","author":"Friesen, H.G.; Tolis, G.","year":"1977","unstructured":"Friesen HG, Tolis G. The use of bromocriptine in the galactorrhoeaamenorrhoea syndromes: the Canadian co-operative study. Clin Endocrinol (Oxf) 1977;6, suppl: 91-9.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJM197902083000606","article-title":"Reduction in size of a pituitary tumour by bromocriptine therapy","volume":"300","author":"McGregor, A.M.; Scanlon, M.F.; Hall, K.; Cook, D.B.; Hall, R.","year":"1979","unstructured":"McGregor AM, Scanlon MF, Hall K, Cook DB, Hall R. Reduction in size of a pituitary tumour by bromocriptine therapy. N Engl J7 Med 1979; 300:291-3.","journal-title":"N Engl J7 Med"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0140-6736(79)92976-3","article-title":"Regression of pituitary prolactinoma after treatment with bromocriptine","volume":"i:","author":"Landolt, A.M.; Wutrich, R.; Fellman, H.","year":"1979","unstructured":"Landolt AM, Wutrich R, Fellman H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1979;i: 1082-3.","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0002-9343(79)91187-2","article-title":"Regression of pituitary tumours, a possible effect of bromocriptine","volume":"66","author":"George, SR, Vurrow; GN, Zimman; B, Ezrin; C.","year":"1979","unstructured":"George SR, Vurrow GN, Zimman B, Ezrin C. Regression of pituitary tumours, a possible effect of bromocriptine. Am_ Med 1979;66:697-702.","journal-title":"Am_ Med"},{"key":"ref_16","first-page":"523","article-title":"Conservative management of pituitary prolactinomas: evidence for bromocriptine-induced regression. Br3'","volume":"87","author":"Hancock, K.W.; Scott, J.S.; Lamb, J.T.; Myles Gibson, R.; Chapman, C.","year":"1980","unstructured":"Hancock KW, Scott JS, Lamb JT, Myles Gibson R, Chapman C. Conservative management of pituitary prolactinomas: evidence for bromocriptine-induced regression. Br3' Obstet Gynaecol 1980;87:523-9.","journal-title":"Obstet Gynaecol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/brain\/99.2.357","article-title":"The pattern-evoked potential in compression of the anterior visual pathways","volume":"99","author":"Halliday, A.M.; Halliday, E.; Kriss, A.; McDonald, W.I.; Mushin, J.","year":"1976","unstructured":"Halliday AM, Halliday E, Kriss A, McDonald WI, Mushin J. The pattern-evoked potential in compression of the anterior visual pathways. Brain 1976;99:357-74.","journal-title":"Brain"},{"key":"ref_18","first-page":"53","article-title":"Hemisphere contributions to the composition of the pattern-evoked potential waveform","volume":"36","author":"Blumhardt, L.D.; Halliday, A.M.","year":"1979","unstructured":"Blumhardt LD, Halliday AM. Hemisphere contributions to the composition of the pattern-evoked potential waveform. Exp Brain Res 1979; 36:53-69.","journal-title":"Exp Brain Res"},{"key":"ref_19","first-page":"\"347","article-title":"Cortical abnormalities in the visual evoked response","volume-title":"of human prolactin. Proc R Soc Med; electrophysiology and pathology","volume":"66","author":"Blumhardt, L.D.; Halliday, A.M.","year":"1981","unstructured":"Blumhardt LD, Halliday AM. Cortical abnormalities in the visual evoked response. In: Spekreijse H,, Apkarian PA, eds. Visual pathways: electrophysiology and pathology. The Hague: W Junk, 1981:347-65. (Proceedings of Documenta Ophthalmologica, series 27.) 20 McNeilly AS. Radioimmunoassay of human prolactin. Proc R Soc Med 1973;66:863-4."},{"key":"ref_20","first-page":"225","article-title":"Plasma prolactin activity in inappropriate lactation","volume":"iii:","author":"Forsyth, I.A.; Besser, G.M.; Edwards, C.R.W.; Francis, L.; Myers, R.P.","year":"1971","unstructured":"Forsyth IA, Besser GM, Edwards CRW, Francis L, Myers RP. Plasma prolactin activity in inappropriate lactation. Br Med J 1971;iii:225-7.","journal-title":"Br Med J"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2265.1973.tb01717.x","article-title":"Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH\/FSH-RH, TRH and hypoglycaemia alone and in combination","volume":"2","author":"Mortimer, C.H.; Besser, G.M.; McNeilly, A.S.; Tunbridge, W.M.G.; Gomez-Pan, A.; Hall, R.","year":"1973","unstructured":"Mortimer CH, Besser GM, McNeilly AS, Tunbridge WMG, Gomez-Pan A, Hall R. Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH\/FSH-RH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf) 1973;2:317-26.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jcem-25-1-39","article-title":"Assessment of thyroid function by the combined use of the serum protein bound iodine and resin uptake of 31I-Triiodothyronine","volume":"25","author":"Clarke, F.; Horn, D.B.","year":"1965","unstructured":"Clarke F, Horn DB. Assessment of thyroid function by the combined use of the serum protein bound iodine and resin uptake of 31I-Triiodothyronine. J Clin Endocrinol Metab 1965;25:39-45.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_23","first-page":"280","article-title":"Reversible insensitivity to androgen in men with untreated gluten enteropathy","volume":"i:","author":"Green, J.R.B.; Goble, H.L.; Edwards, C.R.W.; Dawson, A.M.","year":"1977","unstructured":"Green JRB, Goble HL, Edwards CRW, Dawson AM. Reversible insensitivity to androgen in men with untreated gluten enteropathy. Lancet 1977;i:280-2.","journal-title":"Lancet"},{"key":"ref_24","first-page":"16","article-title":"BrJ_ 25 Dorrell D. The tilted disc","volume":"62","year":"1978","unstructured":"BrJ_ 25 Dorrell D. The tilted disc. Ophthalmol 1978;62:16-20.","journal-title":"Ophthalmol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/255497a0","article-title":"Effects of oestrogen and bromocriptine in vivo secretion and mitosis in prolactin cells","volume":"255","author":"Lloyd, H.M.; Meares, J.D.; Jacobi, J.","year":"1975","unstructured":"Lloyd HM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine in vivo secretion and mitosis in prolactin cells. Nature 1975;255:497-8.","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1126\/science.176.4033.417","article-title":"Ergot-induced inhibition of pituitary tumour growth in rats","volume":"176","author":"Quadri, S.K.; Lu, K.M.; Meites, J.","year":"1972","unstructured":"Quadri SK, Lu KM, Meites J. Ergot-induced inhibition of pituitary tumour growth in rats. Science 1972;176:417-8.","journal-title":"Science"},{"key":"ref_27","first-page":"849","article-title":"Suppression of pituitary tumour growth and function by ergot alkaloids","volume":"33","author":"Macleod, R.M.; Lehmeyer, J.E.","year":"1973","unstructured":"Macleod RM, Lehmeyer JE. Suppression of pituitary tumour growth and function by ergot alkaloids. Cancer Res 1973;33:849-55.","journal-title":"Cancer Res"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jcem-53-4-737","article-title":"Size reduction of macroprolactinomas by bromocriptine or lisuride treatment","volume":"53","author":"Chiodini, P.; Liuzzi, A.; Cozzi, R.","year":"1981","unstructured":"Chiodini P, Liuzzi A, Cozzi R, et al. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. 7 Clin Endocrinol Metab 1981; 53:737-43.","journal-title":"7 Clin Endocrinol Metab"},{"key":"ref_29","first-page":"66","article-title":"Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy","volume":"ii:","author":"Wass, J.A.H.; Moult, P.J.A.; Thorner, M.O.","year":"1979","unstructured":"Wass JAH, Moult PJA, Thorner MO, et al. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 1979;ii:66-9.","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/bmj.2.6192.700","article-title":"Effects of bronsocriptine on pituitary tumour size","volume":"ii:","author":"McGregor, A.M.; Scanlon, M.F.; Hall, R.; Hall, K.","year":"1979","unstructured":"McGregor AM, Scanlon MF, Hall R, Hall K. Effects of bronsocriptine on pituitary tumour size. Br Medy 1979;ii:700-3.","journal-title":"Br Medy"},{"key":"ref_31","first-page":"245","article-title":"Hyperprolactinaemia in men-response to bromocriptine therapy","volume":"i:","author":"Prescott, R.W.G.; Johnston, D.G.; Kendall-Taylor, P.","year":"1982","unstructured":"Prescott RWG, Johnston DG, Kendall-Taylor P, et al. Hyperprolactinaemia in men-response to bromocriptine therapy. Lancet 1982;i: 245-9.","journal-title":"Lancet"},{"key":"ref_32","first-page":"438","article-title":"Rapid regression of pituitary prolactinomas during bromocriptine treatment..7 Clin Endocrinol Metab","volume":"51","author":"Thorner, M.O.; Martin, W.H.; Rogol, A.D.","year":"1980","unstructured":"Thorner MO, Martin WH, Rogol AD, et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment..7 Clin Endocrinol Metab 1980;51:438-42."},{"key":"ref_33","first-page":"311","article-title":"Bromocriptine reduces pituitary tumor size and hypersecretion. Requiem for pituitary surgery ?","volume":"247","author":"Spark, R.F.; Baker, R.; Bienfang, D.C.; Bergland, R.","year":"1982","unstructured":"Spark RF, Baker R, Bienfang DC, Bergland R. Bromocriptine reduces pituitary tumor size and hypersecretion. Requiem for pituitary surgery ? J7AMA 1982;247:311-6."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.42.2.123","article-title":"Transcranial management of pituitary tumours with suprasellar extension","volume":"42","author":"Symon, L.; Jakubowski, J.","year":"1979","unstructured":"Symon L, Jakubowski J. Transcranial management of pituitary tumours with suprasellar extension. 7 Neurol Neurosurg Psychiatry 1979;42: 123-33.","journal-title":"7 Neurol Neurosurg Psychiatry"},{"key":"ref_35","article-title":"Accepted 28","year":"1982","unstructured":"(Accepted 28 April 1982)"},{"key":"ref_36","article-title":"By inflammation","unstructured":"By inflammation."},{"key":"ref_37","article-title":"By thick humours. Medicines appropriated to the reins and bladder are usually called Nephriticals, and are threefold; some cool, others cut gross humours, and a third sort breaks the stone. In the use","volume-title":"notice, that the constitution of the reins and bladder is such, that they abhor all binding medicines because they cause stoppage of urine. Take notice, that the reins and bladder being subject to inflammations endure not very hot medicines. Because the bladder is further remote from the centre of the body than the kidnies are, therefore it requires stronger medicines than the kidnies do, lest the strength of the medicine be spent before it be come to the part afflicted","author":"of all these, take","year":"1616","unstructured":"By thick humours. Medicines appropriated to the reins and bladder are usually called Nephriticals, and are threefold; some cool, others cut gross humours, and a third sort breaks the stone. In the use of all these, take notice, that the constitution of the reins and bladder is such, that they abhor all binding medicines because they cause stoppage of urine. Take notice, that the reins and bladder being subject to inflammations endure not very hot medicines. Because the bladder is further remote from the centre of the body than the kidnies are, therefore it requires stronger medicines than the kidnies do, lest the strength of the medicine be spent before it be come to the part afflicted. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.284.6333.1908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T16:19:29Z","timestamp":1601050769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.284.6333.1908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,6,26]]},"references-count":37,"journal-issue":{"issue":"6333","published-print":{"date-parts":[[1982,6,26]]}},"URL":"https:\/\/doi.org\/10.1136\/bmj.284.6333.1908","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,6,26]]}}}